蛋白酶体抑制剂在恶性血液病靶向治疗中的研究进展

Progression of proteasome inhibitor in the targeted therapy for hematological systemetic malignant tumor

蛋白酶体是一种多酶复合物，能够降解细胞周期调节蛋白，而这些被降解的蛋白控制着细胞周期的进程和细胞凋亡。蛋白酶体抑制剂可通过抑制泛素-蛋白酶体通路（UPP）调节细胞周期，促进细胞凋亡，体内外实验均发现蛋白酶体抑制剂对多种血液系统恶性肿瘤细胞具促凋亡的生物活性，可通过不同的机制引起细胞凋亡。因此蛋白酶体抑制剂是一种新型的肿瘤靶向治疗药物。

Proteasomes is a multienzyme complex. It can degradate cyclin, which control the process of cell cycle and cell apoptosis. Proteasome inhibitor regulate cell cycle and promote cell apoptosis through suppressing UP pathway. Proteasome inhibitor can stimulate apoptosis of various hematological systemetic malignant tumor and cause cell apoptosis through different mechanism in vivo and vitro. Therefore, proteasome inhibitor is a new-style tumor targeted therapy drug.